Abstract
Much of the focus of research on patients with chest pain is directed at technological advances in the diagnosis and management of acute coronary syndrome (ACS), pulmonary embolism (PE), and acute aortic dissection (AAD), despite there being no significant difference at 4 years as regards mortality, ongoing chest pain, and quality of life between patients presenting to the emergency department with noncardiac chest pain and those with cardiac chest pain. This article examines future developments in the diagnosis and management of patients with suspected ACS, PE, AAD, gastrointestinal disease, and musculoskeletal chest pain.
MeSH terms
-
Acute Coronary Syndrome / complications
-
Acute Coronary Syndrome / diagnosis
-
Acute Coronary Syndrome / therapy
-
Anticoagulants / therapeutic use
-
Biomarkers / analysis
-
Chest Pain* / diagnosis
-
Chest Pain* / etiology
-
Chest Pain* / therapy
-
Diagnosis, Differential
-
Diagnostic Imaging
-
Electrocardiography
-
Endoscopy, Gastrointestinal
-
Humans
-
Musculoskeletal Diseases / complications
-
Musculoskeletal Diseases / diagnosis
-
Musculoskeletal Diseases / therapy
-
Platelet Aggregation Inhibitors / therapeutic use
-
Pulmonary Embolism / complications
-
Pulmonary Embolism / diagnosis
-
Pulmonary Embolism / therapy
-
Risk Assessment
-
Time Factors
Substances
-
Anticoagulants
-
Biomarkers
-
Platelet Aggregation Inhibitors